Erika Amore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erika Amore has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Antonina Azzolina
Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy, Consiglio Nazionale delle Ricerche, Via Ugo la Malfa 153, 90146 Palermo, Italy
2 shared publications - Chiara Botto
Lab. of Biocompatible Polymers, Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Via Archirafi 32, 90123 Palermo, Italy
2 shared publications - Emanuela Fabiola Craparo
Lab of Biocompatible Polymers, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, Palermo 90123, Italy
2 shared publications - Gaetano Giammona
Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy
2 shared publications - Maria Luisa Bondì
Istituto per lo Studio dei Materiali Nanostrutturati (ISMN), U.O.S. Palermo, CNR, Via Ugo La Malfa, 153, 90146 Palermo, Italy
2 shared publications - Melchiorre Cervello
Institute of Biomedicine and Molecular Immunology Alberto Monroy, National Research Council (CNR), Palermo, Italy
2 shared publications
Latest Publications
- Open Access
- 13 January 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 3
Correction to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
Following publication of our article [1], we became aware that Roberto Di Gesù had been omitted from the list of authors. The corrected author list and authors’ contribution statement appear below. We apologize for any inconvenience this may have caused.
- 13 January 2018
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 16 (1) , 3
Open AccessCorrection to: Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
Following publication of our article [1], we became aware that Roberto Di Gesù had been omitted from the list of authors. The corrected author list and authors’ contribution statement appear below. We apologize for any inconvenience this may have caused.
- Open Access
- 1 January 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 21
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery.
- 1 January 2014
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 12 (1) , 21
Open AccessEntrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery.